Skip to main content

Professional cross-priming for ovary and prostate cancer

Objective

Immune responses are initiated by antigen presentation mediated by dendritic cells (DC). There is a minority subset of DC highly specialised in starting up cytotoxic T lymphocytes able to kill tumor cells. PROCROP aims to develop in three pilot clinical trials a suitable individualized cancer vaccine technology for castration resistant prostate cancer and metastatic cancer of the ovary that would complement currently available therapies to increase efficacy. The project applies recent compelling knowledge on the identity of the main antigen-presenting DC subsets for vaccine elicitation of cytotoxic T lymphocytes endowed with the ability to seek and destroy tumour cells (such immune mechanism is termed crosspriming). This unique opportunity for superior DCs for immunotherapy comes from the fact that Miltenyi, a successful European biotech company, has the necessary proprietary reagents (anti-BDCA-3 monoclonal antibody and immunomagnetic selection technology), as well as the expertise to clinically develop a strategy of DC isolation and short-term cell culture for immunotherapy. From the point of view of the tumor antigens, processed autologous tumor material will be mixed with defined common tumor antigens in the form of recombinant proteins. This novel combination will permit stronger and broader antitumor immune responses and more accurate monitoring of the ensuing immunity against the tumors. These features should make the novel DC vaccine more efficacious than the currently US-approved DC vaccine PROVENGE and other DCs preparations undergoing trials, such as those derived from monocytes. Three of the leading groups in immunotherapy of cancer in Europe would join forces to develop this individualized cell therapy technology in clinical trials for two highly prevalent and unsatisfactorily managed malignant conditions. Industrial partnership provides the unique advantage of producing a rigorously standardized product for eventual multicentre trials.

Call for proposal

H2020-PHC-2014-2015

See other projects for this call

Sub call

H2020-PHC-2014-two-stage

Coordinator

FUNDACION PARA LA INVESTIGACION MEDICA APLICADA FIMA
Net EU contribution
€ 1 190 000,00
Address
Avenida De Pio Xii 55
31008 Pamplona
Spain

See on map

Region
Noreste Comunidad Foral de Navarra Navarra
Activity type
Research Organisations
Other funding
€ 1 190 000,00

Participants (6)

STICHTING RADBOUD UNIVERSITEIT
Netherlands
Net EU contribution
€ 1 510 000,00
Address
Houtlaan 4
6525 XZ Nijmegen

See on map

Region
Oost-Nederland Gelderland Arnhem/Nijmegen
Activity type
Higher or Secondary Education Establishments
Other funding
€ 1 510 000,00
MILTENYI BIOTEC GMBH
Germany
Net EU contribution
€ 1 345 000,00
Address
Friedrich Ebert Strasse 68
51429 Bergish Gladbach

See on map

Region
Nordrhein-Westfalen Köln Rheinisch-Bergischer Kreis
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Other funding
€ 1 345 000,00
CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CARLOS III (F.S.P.)
Spain
Net EU contribution
€ 655 000,00
Address
Calle Melchor Fernandez Almagro 3
28029 Madrid

See on map

Region
Comunidad de Madrid Comunidad de Madrid Madrid
Activity type
Research Organisations
Other funding
€ 655 000,00
UNIVERSIDAD DE NAVARRA
Spain
Net EU contribution
€ 1 050 000,00
Address
Campus Universitario Edificio Central
31080 Pamplona

See on map

Region
Noreste Comunidad Foral de Navarra Navarra
Activity type
Higher or Secondary Education Establishments
Other funding
€ 1 050 000,00
CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS
Switzerland
Net EU contribution
€ 0,00
Address
Rue Du Bugnon 21
1011 Lausanne

See on map

Region
Schweiz/Suisse/Svizzera Région lémanique Vaud
Activity type
Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
Other funding
€ 0,00
UNIVERSITE DE LAUSANNE
Switzerland
Net EU contribution
€ 0,00
Address
Quartier Unil-centre Bâtiment Unicentre
1015 Lausanne

See on map

Region
Schweiz/Suisse/Svizzera Région lémanique Vaud
Activity type
Higher or Secondary Education Establishments
Other funding
€ 0,00